Igm Biosciences (IGMS) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Igm Biosciences faces significant risks that could adversely impact its business and financial prospects, particularly due to its early-stage development of novel IgM antibodies, which are yet to be proven as viable therapeutic options. The company is confronted with challenges such as the high costs and complexities of clinical trials, potential safety issues with its product candidates, and intense competition from other entities developing similar treatments. Additionally, the manufacturing process for its product candidates is complex, and supply chain issues could further impede progress. Moreover, Igm Biosciences requires substantial funding to continue its operations, and there is no assurance that it will achieve or sustain profitability.
The average IGMS stock price target is $19.89, implying 52.65% upside potential.
To learn more about Igm Biosciences’ risk factors, click here.
